UBS maintains Clorox at Neutral, raises price target to $96 from $91

UBS kept its Neutral rating on Clorox but increased its price target to $96 from $91, suggesting a 6.8% upside from the Nov 2 close of $89.90. Recent analyst price targets for Clorox range from $80 to $99.

Original reporting
Published Nov 3, 2026, 3:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Clorox at Neutral, raises price target to $96 from $91 — source image
Decision brief

The 30-second read

$CLXNeutralLow
01

Why it matters

The main tradable input is the revised price target ($96 vs $91) while the rating remains Neutral, suggesting incremental support rather than a catalyst.

02

Market read

Useful for short-term sentiment and positioning, but lacks new fundamental information.

03

What to watch

The article does not cite any new thesis drivers behind the target change, so traders may discount the update versus catalysts like earnings or guidance.

Relevance 4/10Novelty 4/10Timing: today’s analyst note update, no scheduled company event cited

Background

The piece is an analyst action summary from UBS, not a company disclosure.

Company-level read

Ticker impact

$CLXNeutralMedium confidence
Context

UBS maintained Clorox at Neutral and raised its price target to $96 from $91, implying upside versus the Nov 2 close.

Expected impact

Likely modest upward bias as traders price in the higher target, but follow-through may be capped by the unchanged Neutral rating.

Evidence & confidence

The article provides a specific UBS price-target increase and an implied upside figure, but it is not a new fundamental event like earnings, guidance, or a deal.

Market effects

Limited read-through to consumer staples beyond incremental sentiment for a large household products name.

No direct regional macro or cross-market catalyst described.

Primarily US-listed analyst-target adjustment, with minimal global spillover.

Counterpoint

A higher price target with a Neutral rating may reflect valuation support rather than improved fundamentals, so the market may not re-rate meaningfully.

Key entities

  • Clorox

    UBS maintained Neutral and raised its price target to $96 from $91.

Related articles

$CLXMedAI 8/10

Why is Clorox stock climbing today?

Clorox (CLX) stock rose 1.2% in pre-market trading after reporting fiscal Q1 earnings of $1.55 per share, beating estimates by 45%, with revenue of $1.91B. Sales increased 33% YoY, driven by the GOJO acquisition and organic growth. Analysts upgraded price targets (Evercore ISI to $99, Wells Fargo to $90, JPMorgan to $86), but Goldman Sachs maintained a Sell rating with a $74 target. Management warned of higher input costs and adjusted EPS guidance downward.

$CLXHighAI 8/10

Clorox Co (CLX) (Q1 2027) Earnings Call Highlights: Record Cost Savings and GoJo

Clorox (CLX) reported Q1 2027 earnings, with CEO Linda Rendell and CFO Kevin Bellet discussing organic sales growth of 3.5% to 4.5%, including ERP benefits. They highlighted record cost savings, targeted pricing, and market share improvements in home care and Brita. GoJo synergies are progressing faster than expected, with revised EPS estimates. The company aims for long-term gross margin of 43% to 44% and operating margin of 18%.

$CLXMed

Clorox (CLX) Q1 2027 Earnings Call Transcript

Clorox (CLX) reported Q1 2027 earnings, updating its outlook to reflect $240M in input cost inflation, driven by commodities and transportation. The company expects organic sales growth of 3.5% to 4.5% for the year, with a flat to slightly positive performance in the back half. Clorox also announced Fabian Garcia as its next CEO, effective January. The company is implementing cost savings and targeted pricing to mitigate inflationary pressures.

$CLXMed

Clorox Q1 Earnings Call Highlights

Clorox (CLX) maintained its fiscal-year organic-sales-growth outlook of 3.5% to 4.5%, with Q2 expected to range from flat to down 2%. The company reported share gains in home care, Brita, and Hidden Valley Ranch, while Kingsford and cat litter faced challenges. Clorox is prioritizing pricing, innovation, and GOJO integration, with Fabian Garcia appointed as the next CEO. The company expects positive adjusted EPS impact from synergies in fiscal 2027.